Cargando…
Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis
There is an increasing number of trauma patients presenting on pre-injury antiplatelet (AP) agents attributable to an aging population and expanding cardio- or cerebrovascular indications for antithrombotic therapy. The effects of different AP regimens on outcomes after traumatic brain injury (TBI)...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438446/ https://www.ncbi.nlm.nih.gov/pubmed/36060453 http://dx.doi.org/10.1089/neur.2022.0042 |
_version_ | 1784781826089287680 |
---|---|
author | Mathieu, François Malhotra, Armaan K. Ku, Jerry C. Zeiler, Frederick A. Wilson, Jefferson R. Pirouzmand, Farhad Scales, Damon C. |
author_facet | Mathieu, François Malhotra, Armaan K. Ku, Jerry C. Zeiler, Frederick A. Wilson, Jefferson R. Pirouzmand, Farhad Scales, Damon C. |
author_sort | Mathieu, François |
collection | PubMed |
description | There is an increasing number of trauma patients presenting on pre-injury antiplatelet (AP) agents attributable to an aging population and expanding cardio- or cerebrovascular indications for antithrombotic therapy. The effects of different AP regimens on outcomes after traumatic brain injury (TBI) have yet to be elucidated, despite the implications on patient/family counseling and the potential need for better reversal strategies. The goal of this systematic review and meta-analysis was to assess the impact of different pre-injury AP regimens on outcomes after TBI. In accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, the OVID Medline, Embase, BIOSIS, Scopus, and Cochrane databases were searched from inception to February 2022 using a combination of terms pertaining to TBI and use of AP agents. Baseline demographics and study characteristics as well as outcome data pertaining to intracerebral hematoma (ICH) progression, need for neurosurgical intervention, hospital length of stay, mortality, and functional outcome were extracted. Pooled odds ratios (ORs) and mean differences comparing groups were calculated using random-effects models. Thirteen observational studies, totaling 1244 patients receiving single AP therapy with acetylsalicylic acid or clopidogrel, 413 patients on dual AP therapy, and 3027 non-AP users were included. No randomized controlled trials were identified. There were significant associations between dual AP use and ICH progression (OR, 2.81; 95% confidence interval [CI], 1.19–6.61; I(2), 85%; p = 0.02) and need for neurosurgical intervention post-TBI (OR, 1.61; 95% CI, 1.15–2.28; I(2), 15%; p = 0.006) compared to non-users, but not between single AP therapy and non-users. There were no associations between AP use and hospital length of stay or mortality after trauma. Pre-injury dual AP use, but not single AP use, is associated with higher rates of ICH progression and neurosurgical intervention post-TBI. However, the overall quality of studies was low, and this association should be further investigated in larger studies. |
format | Online Article Text |
id | pubmed-9438446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Mary Ann Liebert, Inc., publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-94384462022-09-02 Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis Mathieu, François Malhotra, Armaan K. Ku, Jerry C. Zeiler, Frederick A. Wilson, Jefferson R. Pirouzmand, Farhad Scales, Damon C. Neurotrauma Rep Original Article There is an increasing number of trauma patients presenting on pre-injury antiplatelet (AP) agents attributable to an aging population and expanding cardio- or cerebrovascular indications for antithrombotic therapy. The effects of different AP regimens on outcomes after traumatic brain injury (TBI) have yet to be elucidated, despite the implications on patient/family counseling and the potential need for better reversal strategies. The goal of this systematic review and meta-analysis was to assess the impact of different pre-injury AP regimens on outcomes after TBI. In accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, the OVID Medline, Embase, BIOSIS, Scopus, and Cochrane databases were searched from inception to February 2022 using a combination of terms pertaining to TBI and use of AP agents. Baseline demographics and study characteristics as well as outcome data pertaining to intracerebral hematoma (ICH) progression, need for neurosurgical intervention, hospital length of stay, mortality, and functional outcome were extracted. Pooled odds ratios (ORs) and mean differences comparing groups were calculated using random-effects models. Thirteen observational studies, totaling 1244 patients receiving single AP therapy with acetylsalicylic acid or clopidogrel, 413 patients on dual AP therapy, and 3027 non-AP users were included. No randomized controlled trials were identified. There were significant associations between dual AP use and ICH progression (OR, 2.81; 95% confidence interval [CI], 1.19–6.61; I(2), 85%; p = 0.02) and need for neurosurgical intervention post-TBI (OR, 1.61; 95% CI, 1.15–2.28; I(2), 15%; p = 0.006) compared to non-users, but not between single AP therapy and non-users. There were no associations between AP use and hospital length of stay or mortality after trauma. Pre-injury dual AP use, but not single AP use, is associated with higher rates of ICH progression and neurosurgical intervention post-TBI. However, the overall quality of studies was low, and this association should be further investigated in larger studies. Mary Ann Liebert, Inc., publishers 2022-08-10 /pmc/articles/PMC9438446/ /pubmed/36060453 http://dx.doi.org/10.1089/neur.2022.0042 Text en © François Mathieu et al., 2022; Published by Mary Ann Liebert, Inc. https://creativecommons.org/licenses/by/4.0/This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Mathieu, François Malhotra, Armaan K. Ku, Jerry C. Zeiler, Frederick A. Wilson, Jefferson R. Pirouzmand, Farhad Scales, Damon C. Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis |
title | Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis |
title_full | Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis |
title_fullStr | Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis |
title_short | Pre-Injury Antiplatelet Therapy and Risk of Adverse Outcomes after Traumatic Brain Injury: A Systematic Review and Meta-Analysis |
title_sort | pre-injury antiplatelet therapy and risk of adverse outcomes after traumatic brain injury: a systematic review and meta-analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438446/ https://www.ncbi.nlm.nih.gov/pubmed/36060453 http://dx.doi.org/10.1089/neur.2022.0042 |
work_keys_str_mv | AT mathieufrancois preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis AT malhotraarmaank preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis AT kujerryc preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis AT zeilerfredericka preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis AT wilsonjeffersonr preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis AT pirouzmandfarhad preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis AT scalesdamonc preinjuryantiplatelettherapyandriskofadverseoutcomesaftertraumaticbraininjuryasystematicreviewandmetaanalysis |